<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="357">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03902548</url>
  </required_header>
  <id_info>
    <org_study_id>JH-147896</org_study_id>
    <nct_id>NCT03902548</nct_id>
  </id_info>
  <brief_title>Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers</brief_title>
  <official_title>A Positron Emission Tomography (PET) Study to Compare the [18F]P16-129 and [18F]Florbetapir for Investigations of Amyloid β Pathology in Subjects With Alzheimer's Disease and Investigate the Biokinetics, Radiation Dosimetry, and Safety of [18F]P16-129 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Five Eleven Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Five Eleven Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the initial safety profile of [18F]P16-129 in healthy volunteers&#xD;
      including dosimetry determination, and compares the uptake and kinetics of [18F]P16-129 with&#xD;
      the FDA approved drug [18F]florbetapir in the brains of Alzheimer's disease patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2018</start_date>
  <completion_date type="Actual">November 2, 2019</completion_date>
  <primary_completion_date type="Actual">November 2, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regional brain uptake of [18F]P16-129 and [18F]florbetapir</measure>
    <time_frame>30 - 90 minutes post injection</time_frame>
    <description>Quantitative estimates of amyloid distribution in brain - SUV and SUVR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative organ [18F]P16-129 activity for estimates of radiation absorbed dose and effective dose</measure>
    <time_frame>0 - 240 min post injection</time_frame>
    <description>dosimetry</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Brain uptake and kinetics in Alzheimer's patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosimetry in healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]P16-129</intervention_name>
    <description>Injection of &lt; 10 mCi [18F]P16-129 followed by PET/CT scanning</description>
    <arm_group_label>Brain uptake and kinetics in Alzheimer's patients</arm_group_label>
    <arm_group_label>Dosimetry in healthy volunteers</arm_group_label>
    <other_name>[18F]D3FSP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part I - Brain uptake in Alzheimer's patients&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          1. Signed and dated written informed consent. Capacity for consent will be determined&#xD;
             using the Alzheimer's Association Guidelines, developed at Johns Hopkins and described&#xD;
             in Alzheimer's Association&#xD;
&#xD;
             Consensus Recommendation: Research consent for cognitively impaired adults:&#xD;
&#xD;
             Guidelines for Institutional Review Boards and Investigators (Alzheimer's Association&#xD;
             2004).&#xD;
&#xD;
          2. Have a study partner able to accompany the subject to all visits and answer questions&#xD;
             about the subject.&#xD;
&#xD;
          3. Male or female, &gt; 50 years of age&#xD;
&#xD;
          4. Have a diagnosis of probable AD, according to the National Institute of Neurological&#xD;
             and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders&#xD;
             Association criteria&#xD;
&#xD;
          5. The patient has a Mini Mental State Examination (MMSE) score at screening of at least&#xD;
             15 and no greater than 26.&#xD;
&#xD;
          6. Female patients must have had her last natural menstruation at least ≥24 months prior&#xD;
             to the Screening Visit or have been surgically sterilized prior to the Screening&#xD;
             Visit. Male patients must use two methods of contraception in combination if his&#xD;
             female partner is of childbearing potential; OR have been surgically sterilized prior&#xD;
             to the Screening Visit.&#xD;
&#xD;
          7. In the opinion of the investigator based on medical history and physical examination,&#xD;
             can safely tolerate tracer administration and the scanning procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of a significant neurological diagnosis (other than AD) that may&#xD;
             influence the outcome or analysis of the scan results; examples include but are not&#xD;
             limited to stroke, traumatic brain injury, space occupying lesions, major head trauma,&#xD;
             and Parkinson's disease.&#xD;
&#xD;
          2. History or presence of any clinically relevant hematological, hepatic, respiratory,&#xD;
             cardiovascular, renal, metabolic, endocrine, or CNS disease or other medical&#xD;
             conditions that are not well controlled, may put the subject at risk, could interfere&#xD;
             with the objectives of the study, or make the subject unsuitable for participation in&#xD;
             the study for any other reason in the opinion of the principal investigator.&#xD;
&#xD;
          3. The patient has a history of seizures, with the exception of childhood febrile&#xD;
             seizures.&#xD;
&#xD;
          4. History of positive HIV, hepatitis B surface antigen (HBsAg), or hepatitis C virus /&#xD;
             antibodies (anti-HCV)&#xD;
&#xD;
          5. Clinically relevant pathological findings in physical examination, ECG, vital signs,&#xD;
             or laboratory values at the screening assessment that could interfere with the&#xD;
             objectives of the study.&#xD;
&#xD;
          6. Have current clinically significant cardiovascular disease. The patient has, at the&#xD;
             Screening Visit: an abnormal ECG that is, in the investigator's opinion, clinically&#xD;
             significant, a QTcF &gt; 470 ms.&#xD;
&#xD;
          7. Has had or is planning to have exposure to ionizing radiation that in combination with&#xD;
             the study-related tracer administrations and scanning procedures would result in a&#xD;
             cumulative exposure that exceeds recommended exposure limits.&#xD;
&#xD;
          8. Contraindications of MRI. Incidental findings on MRI scans that are pathognomonic for&#xD;
             an active disease or pathological process which requires medical intervention will be&#xD;
             exclusionary.&#xD;
&#xD;
          9. History of, or suffers from, claustrophobia or feels that he or she will be unable to&#xD;
             lie still on their back in the MRI or PET scanner.&#xD;
&#xD;
         10. Patients who have received an investigational medication within the last 30 days.&#xD;
             Additionally, the time between the last dose of the previous experimental medication&#xD;
             and enrollment (completion of screening assessments) must be at least equal to 5 times&#xD;
             the terminal half-life of the previous experimental medication.&#xD;
&#xD;
        Part II - Dosimetry in Healthy Volunteers&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          1. Healthy non-smoking males and females, as determined by medical history, physical&#xD;
             examination, vital signs, clinical laboratory tests, and an electrocardiogram.&#xD;
&#xD;
             1.1 Male subjects and their child bearing potential partners must be willing to use a&#xD;
             reliable method of birth control for the duration of the study.&#xD;
&#xD;
             1.2 Female subjects who are of childbearing potential must agree to use an adequate&#xD;
             method of contraception for the duration of the study.&#xD;
&#xD;
          2. Between 18-45 years old, inclusive.&#xD;
&#xD;
          3. BMI between 18-30 kg/m2 inclusive.&#xD;
&#xD;
          4. Have clinical laboratory test results within the reference ranges for the population&#xD;
             or results within acceptable deviations that are not considered by the investigator to&#xD;
             be clinically significant.&#xD;
&#xD;
          5. All subjects and their partners of childbearing potential must commit to use two&#xD;
             methods of contraception, one of which must be a barrier method, from the time of&#xD;
             screening and throughout the study and until follow-up.&#xD;
&#xD;
          6. Less than 195 cm (6 feet and 5 inches) tall in order to accommodate the whole body&#xD;
             scanning.&#xD;
&#xD;
          7. Have sufficient venous access.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Are currently enrolled in or discontinued within the last 30 days from a clinical&#xD;
             trial involving an investigational drug or device (other than the study drug) or are&#xD;
             currently enrolled in any other type of medical research.&#xD;
&#xD;
          2. Are currently experiencing neuropsychiatric illness or severe systemic disease based&#xD;
             on history and physical exam.&#xD;
&#xD;
          3. Have participated in other research protocols in the last year such that radiation&#xD;
             exposure would exceed the annual limits.&#xD;
&#xD;
          4. Pregnant or nursing women.&#xD;
&#xD;
          5. History of head trauma with prolonged loss of consciousness (&gt;10 minutes) or any&#xD;
             neurological condition including stroke or seizure (excluding childhood febrile&#xD;
             seizure) or history of migraine headache.&#xD;
&#xD;
          6. History of any clinically relevant hematological, hepatic, respiratory,&#xD;
             cardiovascular, renal or CNS disease or other medical condition that is capable of&#xD;
             constituting a risk factor when taking the study drug.&#xD;
&#xD;
          7. Suffer from claustrophobia and would be unable to undergo PET scanning.&#xD;
&#xD;
          8. Any confirmed significant allergic reactions against any drug, or multiple allergies.&#xD;
&#xD;
          9. Currently uses prescription medications, over-the-counter drugs or herbal remedies&#xD;
             such as St. Johns Wort) which cannot be discontinued 14 days (or &lt; 5 half-lives,&#xD;
             whichever is longer), prior to the PET scan and throughout the study. Exceptions&#xD;
             include daily multiple vitamins.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins Medical Institutions</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

